Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTBK1 | Q5TCY1 | 5/20 | 0.65 |
| ▸ | TTBK2 | Q6IQ55 | 5/20 | 0.65 |
| ▸ | EGFR | P00533 | 3/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.62 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.62 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | PDE5A | O76074 | 1/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.55 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | OXTR | P30559 | 1/20 | 0.54 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.53 |
| ▸ | CDK1 | P06493 | 1/20 | 0.53 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24804993 | 0.83 | HDAC6 (0.66) | TTBK1TTBK2EGFRHDAC6HTT | |
| SCHEMBL4354437 | 0.81 | JAK2 (0.68) | TTBK1TTBK2EGFRNR2F2HDAC6 | |
| SCHEMBL29123839 | 0.81 | CYP1A2 (0.59) | TTBK1TTBK2MEN1KMT2AKDM4E | |
| SCHEMBL30598757 | 0.81 | CYP1A2 (0.59) | TTBK1TTBK2MEN1KMT2AKDM4E | |
| SCHEMBL22346237 | 0.80 | HDAC6 (0.62) | TTBK1TTBK2EGFRNR2F2HDAC6 | |
| SCHEMBL2253412 | 0.80 | EGFR (0.61) | EGFRPOLBNR2F2HTTMEN1 | |
| Hydrochloric Acid SCHEMBL8888083 | 0.79 | LMNA (0.67) | EGFRPOLBNR2F2HTTMEN1 | |
| SCHEMBL723440 | 0.78 | CDK1 (0.59) | EGFRPOLBNR2F2HTTMEN1 | |
| SCHEMBL3112115 | 0.77 | EGFR (1.00) | EGFRPOLBNR2F2HTTMEN1 | |
| SCHEMBL24881479 | 0.76 | TTBK1 (1.00) | TTBK1TTBK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111712498-B | Substituted bicyclic heterocyclic compounds as PRMT5 inhibitors | 鲁平有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-11014926-B2 | Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit MNK1 and MNK2 | EFFECTOR THERAPEUTICS, INC. (US) | 2021-05-25 | — | — | US | disclosed |
| US-20190330216-A1 | PYRROLO-, PYRAZOLO-, IMIDAZO-PYRIMIDINE AND PYRIDINE COMPOUNDS THAT INHIBIT MNK1 AND MNK2 | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2019-10-31 | — | — | US | disclosed |
| EP-3368533-A1 | PYRROLO-, PYRAZOLO-, IMIDAZO-PYRIMIDINE AND PYRIDINE COMPOUNDS THAT INHIBIT MNK1 AND MNK2 | Effector Therapeutics Inc. (US) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017075412-A1 | PYRROLO-, PYRAZOLO-, IMIDAZO-PYRIMIDINE AND PYRIDINE COMPOUNDS THAT INHIBIT MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| WO-2017075412-A1 | PYRROLO-, PYRAZOLO-, IMIDAZO-PYRIMIDINE AND PYRIDINE COMPOUNDS THAT INHIBIT MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (US) | 2017-05-04 | — | — | WO | disclosed |
| US-20170121339-A1 | PYRROLO-, PYRAZOLO-, IMIDAZO-PYRIMIDINE AND PYRIDINE COMPOUNDS THAT INHIBIT MNK1 AND MNK2 | EFFECTOR THERAPEUTICS INC (US) | 2017-05-04 | — | — | US | disclosed |
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | BIOGEN IDEC MA INC. | 2017-02-02 | — | — | US | disclosed |
| US-9273028-B2 | Heterocyclic tyrosine kinase inhibitors | BIOGEN MA INC. (US) | 2016-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190330216-A1 | PYRROLO-, PYRAZOLO-, IMIDAZO-PYRIMIDINE AND PYRIDINE COMPOUNDS THAT INHIBIT MNK1 AND MNK2 | NEK9, NEK2, TYK2 | TTBK1 69/4885TTBK2 76/4885EGFR 2188/4885 |
| US-20170121339-A1 | PYRROLO-, PYRAZOLO-, IMIDAZO-PYRIMIDINE AND PYRIDINE COMPOUNDS THAT INHIBIT MNK1 AND MNK2 | NEK9, NEK2, TYK2 | TTBK1 65/4885TTBK2 76/4885EGFR 2155/4885 |
| US-20170027956-A1 | HETEROCYCLIC TYROSINE KINASE INHIBITORS | TEC, ABL1, LCK | TTBK1 136/4885TTBK2 143/4885EGFR 124/4885 |
| US-11014926-B2 | Pyrrolo-, pyrazolo-, imidazo-pyrimidine and pyridine compounds that inhibit MNK1 and MNK2 | NEK9, NEK2, TYK2 | TTBK1 69/4885TTBK2 76/4885EGFR 2188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.